Epidemiology of mucormycosis: Review of 18 cases in a tertiary care hospital

Medical Mycology

Volumn 48, Issue 2, 2010, Pages 245-254

  Saegeman, V ^a   Maertens, J ^a   Ectors, N ^a   Meersseman, W ^a   Lagrou, K ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Epidemiology; Mucormycosis; Tertiary care hospital

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; DEXAMETHASONE; METHYLPREDNISOLONE; POSACONAZOLE;

ADULT; AGED; ANTIMICROBIAL THERAPY; ASPERGILLUS; BED; BRAIN INFECTION; CLINICAL ARTICLE; DEBRIDEMENT; DERMATOMYCOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; INCIDENCE; LUNG INFECTION; MALE; MIXED INFECTION; MORTALITY; MUCORALES; MUCORMYCOSIS; MYCETOMA; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDY; REVIEW; RHIZOPUS; SURVIVAL RATE; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL; HOSPITAL; IMMUNOCOMPROMISED PATIENT; ISOLATION AND PURIFICATION; LUNG DISEASES, FUNGAL; MICROBIOLOGY; MIDDLE AGED; MUCOR; NONPARAMETRIC TEST; RADIOGRAPHY; RISK FACTOR;

ADULT; AGED; FEMALE; HOSPITALS; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; MUCOR; MUCORMYCOSIS; RETROSPECTIVE STUDIES; RHIZOPUS; RISK FACTORS; STATISTICS, NONPARAMETRIC;

ASPERGILLUS; MUCORALES; RHIZOPUS;

EID: 76649099771     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903059477     Document Type: Review

References (31)

1. Hibbett DS, Binder M, Bischoff JF, e t al. A higher-level phylogenetic classifi cation of the fungi. Mycol Res 2007; 11: 509-547 .
2. Chayakulkeeree M, Ghannoum M, Perfect J. Zygomycosis: the reemerging fungal infection. Eur J Clin Microbiol Infect Dis 2006; 25: 215-229 .
3. Bouza E, Munoz P, Guinea J. Mucormycosis: an emerging disease?. Clin Microbiol Infect 2006; 12 ( Suppl. 7 ): 7-23 .
4. Maertens J, Demuynck H, Verbeken E, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of fi ve cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999; 24: 307-312 .
5. Richardson M, Koukila-Kahkola P, Shankland G, . R hizopus , Rhizomucor , Absidia , and other agents of systemic and subcutaneous Zygomycoses . In: Murray P, Baron E, Jorgensen J, Pfaller M, Yolken R, Manual of Clinical Microbiology 8th edn . Washington , DC : ASM Press , 2003 : 1761-1780 .
6. Roden M, Zaoutis T, Buchanan W, et al. Epidemiology and outcome of Zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653 .
7. Tobon A, Arango M, Fernandez D, Restrepo A. Mucormycosis (Zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003; 36: 1488-1491.
8. Kontoyiannis D, Lionakis M, Lewis R, et al. Zygomycosis in a tertiary- care cancer center in the era of Aspergillus -active antifungal therapy: a case-control observational study of 27 recent cases. JID 2005; 191: 1350-1360 .
9. Greenberg R, Scott L, Vaughn H, Ribes J. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17: 517-525 .
10. Marty F, Cosimi L. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. New Engl J Med 2004; 350: 950-952 .
11. Siwek G, Dodgson K, de Magalhaes-Siverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584-587 .
12. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005; 40: 770-771 .
13. Vigouroux S, Morin O, Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005; 40 : e35-e37.
14. Kauffman C. Zygomycosis: reemergence of an old pathogen. C lin Infect Dis 2004; 39: 588-590 .
15. Ascioglu S, Rex J, de Pauw B, e t al. Defi ning opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14 .
16. Safdar A, O'Brien S, Kouri I. Effi cacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplantation 2004; 34: 467 .
17. Marr K, Carter R, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917 . (Pubitemid 34229758)
18. Dannaoui E, Meletiadis J, Mouton J, et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45-52 .
19. Chakrabarti A, Das A, Sharma A, e t al. Ten years' experience in zygomycosis at a tertiary care center in India. J Infect 2001; 42: 261-266 .
20. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leukemia Lymphoma 2004; 45: 1351-1360 .
21. Petrikkos G, Skiada A, Sambatakou H, e t al. Mucormycosis: ten-year experience at a tertiary-care center in Greece. Eur J Clin Microbiol Infect Dis 2003; 22: 753-756 .
22. Greenberg R, Mullane K, van Burik J-A, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-133 .
23. Lehrer R, Howard D, Sypherd P, et al. Mucormycosis. A rch Intern Med 1980; 93: 93-108 .
24. Pagano L, Offi dani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica 2004; 89: 207-214 .
25. Ribes J, Vanover-Sams C, Baker D. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236-301 .
26. Bigby T, Serota M, Tierny L, Matthay M. Clinical spectrum of pulmonary mucormycosis. Chest 1986; 89: 435-439 .
27. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41: 60-66 .
28. Kontoyiannis D, Wessel V, Bodey G, Rolston K. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000: 30: 851-856 .
29. Cummings J, Jamison G, Boudreaux J, et al. Cross-reactivity of non- Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Micr Infec Dis 2007; 59: 113-115 .
30. Swanink C, Meis J, Rijs A, Donnelly J, Verweij P. Specifi city of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 1997; 35: 257-260 .
31. Sims C, Ostrosky-Zeichner L. Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center. Arch Med Res 2007; 38: 90-93 .